Cibinqo is used to treat adults and adolescents 12 years of age and older with moderate-to-severe atopic dermatitis, also known as atopic eczema. It contains the active substance abrocitinib and works by targeting a protein called JAK1, reducing inflammation and itch in atopic dermatitis.
Cibinqo is a pink tablet and comes in three different strengths: 200mg, 100mg, 50mg.
The medicine can only be obtained with a prescription.
For more information on this product please visit the electronic Medicines Compendium (eMC)
▼ This medicine is subject to additional monitoring.
If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.
Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.
PP-CIB-GBR-0079 / November 2021